Prestigious Southern California health plan contracts with Biocept to make the Company's Target Selector™ tests available in-network for its patients with cancer
- Reported revenues of $1.3 million in 2Q 2017 vs. $663,000 in 2Q 2016, up 93%, or 64% excluding the impact of conversion to accrual-based revenue recognition- Launch of "AND" campaign supports growth in test volume both sequentially and year-over-year- New provider agreements with both Scripps Health Plan and MediNcrease expand patient access to Biocept's proprietary liquid biopsy test platform- Secures $2.2 million investment from Ally Bridge LB Healthcare Master Fund- Evaluating strategic opportunities in China with Ally Bridge's Chinese affiliate- Company to host conference call at 4:30 p.m. Eastern time today
Patented blood collection tubes developed by Biocept validated to preserve ctDNA for up to 96 hours at room temperature allowing for intact shipping of liquid biopsy samples from regions around the world
Leading clinical investigator to utilize Biocept's liquid biopsy tests for the detection of ALK rearrangements at baseline and to monitor treatment response and resistance mechanisms over time
SAN DIEGO , Aug. 28, 2017 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W.
Expands commercial offering to 15 clinically actionable biomarker tests, including key validated alterations listed in the NCCN Guidelines® for metastatic melanoma and colorectal cancer
First and only platform that enables local pathologists to obtain molecular biomarker information from a simple blood sample using cutting-edge circulating tumor cell (CTC) technology
